Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"

Go back to Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"

Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign

March 1, 2016 7:01 AM EST

Mizuho Securities maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $34.00 (from $36.00), following the company's 4Q earnings report. HZNP reported a strong revenues of $244.5M and EPS of $0.63 vs. consensus estimates of $240.8M and $0.61. Mgmt indicated the... More

Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Despite Sell-Off; Says Business is Sustainable

February 29, 2016 3:37 PM EST

Piper Jaffray maintained an Overweight rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $44.00 (from $46.00), following the company's 4Q earnings report. Horizon reported adjusted EPS of $0.63 on revenues of $245M, coming in ahead of Street estimates. Sales from the primary care business grew 10% sequentially in 4Q15 over 3Q15, with management citing... More